

mammal when administered to an apical surface of an epithelial barrier of the mammal, and wherein the pharmaceutical preparation is an oral formulation, an aerosol formulation or a nasal formulation.

2
Cl. ~~26~~ The pharmaceutical preparation of claim ~~25~~, wherein the FcRn binding partner is non-specific IgG or a FcRn binding fragment of IgG.

3
Cl. ~~27~~ The pharmaceutical preparation of claim ~~25~~, wherein the FcRn binding partner is an Fc fragment of IgG.

4
Cl. ~~28~~ The pharmaceutical preparation of claim ~~25~~, wherein the antigen is covalently coupled to the FcRn binding partner.

5
Cl. ~~29~~ The pharmaceutical preparation of any one of claims ~~25~~, ~~26~~, ~~27~~ and ~~28~~, wherein the unit dosage is an oral formulation.

6
Cl. ~~30~~ The pharmaceutical preparation of claim ~~29~~, wherein the oral formulation is a solid oral formulation, an elixir or a syrup.

7
Cl. ~~31~~ The pharmaceutical preparation of any one of claims ~~25~~, ~~26~~, ~~27~~ and ~~28~~, wherein the unit dosage is an aerosol formulation.

8
Cl. ~~32~~ The pharmaceutical preparation of claim ~~31~~, wherein the aerosol formulation comprises a propellant.

9
Cl. ~~33~~ The pharmaceutical preparation of any one of claims ~~25~~, ~~26~~, ~~27~~ and ~~28~~, wherein the pharmaceutical preparation is a nasal formulation.

10
Cl. ~~34~~ The pharmaceutical preparation of any one of claims ~~25~~, ~~26~~, ~~27~~ and ~~28~~, wherein the formulation is nonaseptic.

Cl. 35 A pharmaceutical preparation for suppressing an immune response comprising:

- (i) a conjugate of an antigen and an FcRn binding partner, wherein the antigen is selected from the group consisting of:
 - an antigen that is characteristic of an autoimmune disease, and
 - an antigen that is characteristic of an allergen; and
- (ii) a pharmaceutically acceptable carrier, wherein the preparation is formulated as a unit dosage containing an effective amount of the conjugate for suppressing the immune response of a mammal when administered to an apical surface of an epithelial barrier of the mammal, and wherein the unit dosage is an oral formulation, an aerosol formulation or a nasal formulation.

Cl. 36 The pharmaceutical preparation of claim 35, wherein the FcRn binding partner is non-specific IgG or a FcRn binding fragment of IgG.

Cl. 37 The pharmaceutical preparation of claim 35, wherein the FcRn binding partner is an Fc fragment of IgG.

Cl. 38 The pharmaceutical preparation of claim 35, wherein the antigen is covalently coupled to the FcRn binding partner.

Cl. 39 The pharmaceutical preparation of any one of claims 35, 36, 37, and 38, wherein the unit dosage is an oral formulation.

Cl. 40 The pharmaceutical preparation of claim 39, wherein the oral formulation is a solid oral formulation, an elixir or a syrup.

Cl. 41 The pharmaceutical preparation of any one of claims 35, 36, 37, and 38, wherein the unit dosage is an aerosol formulation.

Cl. 42 The pharmaceutical preparation of claim 41, wherein the aerosol formulation comprises a propellant.

B

Cl. 43 The pharmaceutical preparation of any one of claims 35, 36, 37, and 38, wherein the unit dosage is a nasal formulation.

Cl. 44 The pharmaceutical preparation of any one of claims 35, 36, 37, and 38, wherein the unit dosage is nonaseptic.

Cl. 45. A pharmaceutical preparation for application to an apical surface of an epithelial barrier comprising:

a conjugate of an agent and an FcRn binding partner, wherein the agent is a cytokine, and

a pharmaceutically-acceptable carrier, wherein the preparation is formulated as a unit dosage containing the conjugate in an effective amount, and wherein the pharmaceutical preparation is an oral formulation, an aerosol formulation or a nasal formulation.

Cl. 46 The pharmaceutical preparation of claim 45, wherein the FcRn binding partner is non-specific IgG or a FcRn binding fragment of IgG.

Cl. 47 The pharmaceutical preparation of claim 45, wherein the FcRn binding partner is an Fc fragment of IgG.

Cl. 48 The pharmaceutical preparation of claim 45, wherein the agent is covalently coupled to the FcRn binding partner.

Cl. 49 The pharmaceutical preparation of any one of claims 45, 46, 47 and 48, wherein the unit dosage is an oral formulation.

Cl. 50 The pharmaceutical preparation of claim 49, wherein the oral formulation is a solid oral formulation, an elixir or a syrup.

Cl. 51 The pharmaceutical preparation of any one of claims 45, 46, 47 and 48, wherein the unit dosage is an aerosol formulation.

Cl. 52 The pharmaceutical preparation of claim 51, wherein the aerosol formulation comprises a propellant.

Cl. 53 The pharmaceutical preparation of any one of claims 45, 46, 47 and 48, wherein the pharmaceutical preparation is a nasal formulation.

Cl. 54 The pharmaceutical preparation of any one of claims 45, 46, 47 and 48, wherein the formulation is nonaseptic.

Cl. 55 The pharmaceutical preparation of claim 48, wherein the cytokine is erythropoietin.

Cl. 56. The pharmaceutical preparation of claim 48, wherein the cytokine is α , β , or γ -interferon.

Cl. 57 The pharmaceutical preparation of claim 48, wherein the cytokine is an interleukin.

Cl. 58 The pharmaceutical preparation of claim 48, wherein the cytokine is tumor necrosis factor.

Cl. 59 The pharmaceutical preparation of claim 48, wherein the cytokine is a colony-stimulating factor.

Cl. 60 The pharmaceutical preparation of claim 48, wherein the cytokine is a growth factor.--

REMARKS

Claims 1-24 were canceled. New claims 25-60 have been added. No new matter has been added. The Examiner has restricted the application into four different groups. Applicants hereby elect Group II, drawn to pharmaceutical compositions, for prosecution. The specific therapeutic elected is "protein" from the "cell surface" of "hepadnaviridae" Applicants also select the Fc

B